BIO from the BAYOU · 2026-06-17 · 27 min
What does it take to move from the lab bench to the venture side of biotech, and what are investors looking for in the next generation of breakthrough companies? In this episode, Elaine Hamm, PhD, sits down with Kevin White, PhD, Executive Director of the Boehringer Ingelheim Venture Fund, to discuss his journey from academic science to pharmaceutical R&D and ultimately to venture investing. Kevin shares how his scientific background shapes his investment philosophy, what it's like joining one of biotech's leading corporate venture funds, and the therapeutic areas he believes will define the future of healthcare. Along the way, he offers candid advice for founders navigating today's investment landscape and explains why curiosity, adaptability, and a willingness to embrace discomfort are essential for success. In this episode, you'll discover: Why being uncomfortable can be one of the best catalysts for growth. How the Boehringer Ingelheim Venture Fund approaches investing, from exploring "white space" opportunities to supporting innovations aligned with the company's therapeutic priorities.
Episode 143: Why Animal Health Is the Next Frontier for Biotech Innovation72 / 100Episode 142: How ARPA-H is Reimagining Women’s Health and Maternal CareEpisode 140: The Growing Role of AI in Healthcare, Biotech, and Drug DevelopmentEpisode 139: How to Understand Venture Math - The Numbers Behind Biotech Innovation (RE-RELEASE)Episode 138: Building Biotech Across Borders - Translational Science, Hearing Loss, and the Reality of Drug Development